Terbinafine for Biochemically Recurrent Prostate Cancer (TerbinaPro)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
TerbinaPro is a phase II drug-repurposing study evaluating oral Terbinafine in patients with biochemical recurrence of prostate cancer after prior local treatment with curative intent. When local salvage strategies have been exhausted, recurrence usually reflects micro-metastatic disease without clearly visible metastases on imaging. Standard therapy with androgen deprivation or androgen-receptor pathway inhibitors can effectively control disease but is associated with substantial side effects and negative impact on quality of life. Terbinafine is a long-licensed, generic antifungal drug that inhibits squalene epoxidase (SQLE), an enzyme that may play a role in prostate cancer progression. Preclinical and limited clinical data suggest potential anti-cancer activity.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Po ukończeniu leczenia raka prostaty (chirurgia, radioterapia lub inne metody) i wyczerpaniu standardowych opcji leczenia
- •Poziom testosteronu w normie (nie poddawany leczeniu obniżającemu testosteron, lub testosteron wrócił do normy)
- •Brak widocznych przerzutów do odległych narządów w badaniach obrazowych
- •Podwyższony poziom PSA (odpowiednio ≥1 lub ≥2 ng/ml w zależności od rodzaju wcześniejszego leczenia)
- •Potwierdzony wzrost PSA w co najmniej dwóch pomiarach w odstępie minimum 2 tygodni
- •Pacjent nie chce lub nie potrzebuje standardowego leczenia hormonalnego zdaniem lekarza
✗ Disqualifies
- •Przewlekła lub ostra choroba wątroby
- •Historia choroby autoimmunologicznej (toczeń czerwony lub pokrewne zaburzenia)
- •Rzadki typ raka prostaty (neuroendokrynny lub drobnokomórkowy)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 16, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (11)
Kantonsspital Baden
Baden, Switzerland
Universitätsspital Basel
Basel, Switzerland
EOC - Istituto Oncologico della Svizzera Italiana
Bellinzona, Switzerland
Kantonsspital Graubünden
Chur, Switzerland
Spital Thurgau AG
Frauenfeld, Switzerland
Hôpitaux Universitaires Genève HUG
Geneva, Switzerland
Luzerner Kantonsspital
Lucerne, Switzerland
TBZO Tumor- und BrustZentrum Ostschweiz - Rapperswil
Rapperswil, Switzerland
HOCH Health Ostschweiz - Kantonsspital St. Gallen
Sankt Gallen, Switzerland
Kantonsspital Winterthur
Winterthur, Switzerland
Universitätsspital Zürich USZ
Zurich, Switzerland
Trial contact
Stefanie Röthlisberger, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/17/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.